Fatty acids and consequently diet play an essential role in the formation of inflammatory mediators involved in the pathogenesis of asthma. Because intake variations of omega-6 (n-6) and omega-3 (n-3) fatty acids ultimately determine cell membrane incorporation, changes in diet have the potential to modify downstream production of inflammatory mediators derived from these compounds. It has long been hypothesized that decreasing the n-6/n-3 ratio could reduce the production of more proinflammatory mediators while increasing the formation of downstream metabolites that can serve to limit or resolve inflammation. In turn, these changes would result in improved asthma outcomes or would lower the risk for asthma incidence. This review will focus on the role of fatty acid inflammatory and resolving mediators and will summarize the clinical and epidemiologic data on how diet and obesity alter fatty acid profiles that can contribute to asthma.
synthase, and it has been shown that there is a positive correlation of PGD 2 concentration to asthma severity in bronchoalveolar lavage fluid. 8 PGD 2 acts through the thromboxane GPCR, the PGD 2 receptor 1 (DP1), and the chemoattractant receptor-homologous molecule expressed on T H 2 lymphocytes (CRTH2/DP2). 8 The thromboxane GPCR promotes smooth muscle constriction that likely contributes to bronchoconstriction in asthmatic patients. CRTH2 activation on T H 2 lymphocytes, eosinophils, and basophils results in enhanced chemotaxis and activation. CRTH2 receptor binding also induces cytokine production that might play a role in IgE activation by mast cells. 8 
CysLTs
CysLTs are also key mediators of asthma. LTs are derived from AA and synthesized through the 5-LO pathway in conjunction with 5-LO activating protein to catalyze the oxidation of AA to LTA 4 . The epoxide ring of LTA 4 is opened by LTA 4 hydrolase to form LTB 4 or it is conjugated to glutathione by LTC 4 synthase to form LTC 4 . LTC 4 is transported out of the cell by multidrug resistance-associated protein 1. LTC 4 is then subjected to extracellular metabolism to form LTD 4 (loss of glutamine) and LTE 4 (loss of glycine). 1 These 3 LTs, LTC 4 , LTD 4 , and LTE 4 , comprise the CysLTs. Eosinophils and mast cells are primarily responsible for the synthesis of CysLTs in the context of asthma. 1, 2 Bronchoconstriction, the initiation of proinflammatory cytokine production, and airway remodeling have all been attributed to CysLTs. Additionally, CysLTs have been implicated in the trafficking and degranulation of eosinophils in the lungs, increased microvascular permeability leading to pulmonary edema, and increased mucus secretion. 1, 9 Unfortunately, only 50% of asthmatic patients show clinical responses to CysLT receptor agonists. 9 
PRORESOLVING MEDIATORS
A class of inflammation-resolving fatty acids derived from AA, EPA, and DHA exist that are dihydroxy or trihydroxy in nature. The AA-derived lipoxins and the EPA-and DHAderived resolvins, protectins, and maresins are produced by dualenzyme reactions during acute inflammation and are proposed to mediate resolution. 10 These mediators block neutrophil recruitment, promote infiltration and activation of monocytes, and induce phagocytosis and lymphatic clearance of apoptotic neutrophils by activated macrophages. 10 These polyhydroxylated species require transcellular biosynthesis, the sequential actions of LOs from neighboring cells (ie, 5-LO/12-LO or 15-LO/5-LO), or they can be formed by a combination of COX-2 and cytochrome P450 or LO. 10, 11 The EPA-derived resolvin E1 was shown to dampen airway inflammation and airway hyperresponsiveness (AHR) in a mouse model of asthma. 12 Mice administered resolvin E1 had lower eosinophil and lymphocyte recruitment, lower IL-13 and OVA-specific IgE levels, and a lower response to methacholine challenge compared with controls. 12 A review by Uddin and Levy 4 in 2011 summarizes the proresolving role of resolvins in pulmonary inflammation. In a study comparing patients with aspirin-intolerant asthma (AIA) with those with aspirin-tolerant asthma, Sanak et al 13 reported a reduced generation of lipoxin A 4 (LXA 4 ) and aspirintriggered LXA 4 in patients with AIA. 13 However, Celik et al 14 found similar levels of LXA 4 in both patients with AIA and those with aspirin-tolerant asthma. This difference might be attributed to a misclassification of asthmatic patients because LXA 4 levels are consistently lower in patients with severe asthma, regardless of aspirin tolerance. 7 The actions of these proresolving fatty acids are mediated by their binding to specific GPCRs, including CMKLR1, BLT1, ALX/FPR2, and GPR32. 4 Additionally, these proresolving species have also been shown to trigger the expression of anti-inflammatory mediators, such as TGF-β and IL-10. 4 Fat-1 mice 15 express a Caenorhabiditis elegans desaturase that converts n-6 to n-3 fatty acids, thus increasing endogenous anti-inflammatory and proresolving n-3 metabolites. These mice additionally showed a decrease in levels of AA-derived eicosanoids, decreased allergic airway inflammation, and decreased response to methacholine challenge compared with those seen in control mice that were OVA challenged. 15 
ELECTROPHILIC FATTY ACIDS
Polyunsaturated fatty acid (PUFA) oxidation to an α, β-unsaturated ketone or epoxide and the addition of nitrogen dioxide ( • NO 2 ) to an alkene result in the formation of electrophilic fatty acid species. Many of these electrophilic fatty acids, such as 17-oxo-DHA, 15deoxy Δ12,14 -PGJ 2 , and nitro-oleic acid (NO 2 -OA), have been structurally characterized and described as downstream metabolites of n-3 and n-6 PUFAs, but not all have been defined with regard to their biological function, despite their abundance. 5, 16 Electrophilic fatty acids function through the posttranslational modification of proteins and transcription factors. Multiple classes of electrophilic signaling molecules are expected to have unique patterns of downstream signaling. Electrophilic fatty acids will adduct susceptible, nucleophilic amino acid residues, such as cysteine and histidine. This adduction induces alterations in protein structure, function, and subcellular distribution. 17 The targets for electrophilic fatty acid modification are thus diverse, yielding pleiotropic and sometimes reversible effects on an array of key signaling pathways. The oxo-DHA and oxo-EPA species inhibit proinflammatory cytokine and • NO production and activate Nrf2-dependent gene expression. 16 Although dependent on concentration, target specificity, cell type, metabolism, and reversibility, 18,19 many of these effects provide beneficial outcomes in the context of inflammation and play a potential role in asthma. 20 Aside from Nrf2, other key target proteins for electrophilic fatty acids include the peroxisome proliferator activator receptor γ (PPARγ) and nuclear factor κB. 5 Importantly, the endogenous production of these molecules is often a result of pro-oxidative and stress conditions, thus providing a rheostat mechanism for resolving the inflammatory environment.
A recent article by Reddy et al 21 demonstrated that 10-NO 2 -OA decreased airway inflammation and AHR after methacholine challenge to the same extent as fluticasone in a mouse model using ovalbumin as the challenge. In addition, 10-NO 2 -OA, but not fluticasone, stimulates neutrophil apoptosis and phagocytosis. This was attributed to an increase in PPARγ activity. 21 In vitro studies showed that 10-NO 2 -OA significantly upregulated CD36 expression by alveolar macrophages. This was in contrast to fluticasone treatment, which abolished CD36 expression. 21
DIET AND ASTHMA
It has been hypothesized that variations in asthma prevalence across populations and the increase in asthma burden seen in westernized societies over past decades might be related to a combination of a progressively higher intake of n-6 fatty acids, such as LA, which is found in margarine and vegetable oils, and a lower intake of n-3, which is found in marine oils. 22 This concept is largely supported by epidemiologic studies showing that populations with higher n-6 fatty acid consumption have greater asthma prevalence in contrast to those consuming average higher n-3 fatty acid diets, such as the Eskimos. 23 Given that n-3 fatty acids produces eicosanoids that are less proinflammatory (PGE 3 and LTB 5 series) than those derived from n-6 fatty acids (PGD 2 and LTB 4 series) and because downstream metabolites of n-3 fatty acids have the potential to resolve inflammation, the hypothesis that n-3 fatty acid intake could improve asthma by reducing inflammation seems biologically plausible. However, the lack of consistency across observational studies and clinical trials (Table  I) [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] certainly raises the possibility that n-3 fatty acids might not be as universally effective as originally considered. Therefore it is possible that these compounds are only effective in select asthma phenotypes.
Observational studies have not consistently shown in children or adults that increased n-3 fatty acid intake is associated with improved FEV 1 , respiratory symptoms, or asthma control. Similarly, some studies have shown that lower n-3 fatty acid levels or decreased n-3/n-6 ratios are protective for asthma. Paradoxically, increased n-3 intake was related to higher wheeze prevalence (Table I ). In addition to the residual confounders from many potential biases associated with n-3 fatty acid intake, the lack of consistency in results across observational studies might relate to many ways that fatty acid consumption is estimated; although some studies use food frequency questionnaires, others rely on plasma or cell membrane levels (Table I) .
Several randomized clinical trials have been conducted to date for the treatment of asthma (Table II) . [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] As with observational studies, the use of diverse clinical end points for study outcomes, in addition to different combinations of n-3 fatty acid concentration and duration, makes it difficult to appreciate whether this intervention is useful. However, pooled estimates derived from a Cochrane meta-analysis of 9 randomized clinical trials did not show improvements in clinical outcomes, including bronchial hyperresponsiveness. 51 Therefore the study authors found insufficient evidence to recommend the use of n-3 fatty acid products to improve the health of asthmatic patients. Considering that asthma is a complex syndrome comprised of diseases with different clinical phenotypes, select asthmatic patients could benefit more from taking n-3 fatty acids or, alternatively, be harmed more by being exposed to higher concentrations of n-6 fatty acids. Among atopic asthmatic patients, n-3 fatty acid supplementation has been shown to reduce exhaled nitric oxide levels and sputum eosinophil counts in asthmatic patients pre-exposed to sensitized allergens; however, these results have not been widely replicated. 40 Two well-conducted randomized studies have shown that n-3 fatty acid supplementation significantly reduces the exerciseinduced FEV 1 decrease and reduces use of short-acting β-agonists, 40-42,52 although a similar intervention was not useful among patients with mild-to-moderate asthma exercising with less intensity under ambient conditions. 53 There have been a limited number of projects evaluating whether n-3 fatty acid exposure in utero could reduce the incidence of atopy and asthma in offspring. Although the majority show some degree of protection, this has not been a consistent result across all studies. Protection is thought to occur through a mechanism involving n-3 fatty acid-mediated reductions in PGE 2 levels, which can subsequently decrease T H 2-related cytokine and IgE levels. 43, 54, 55 Although fish oil supplementation does not result in improved asthma control, it might be that management of overall caloric intake of saturated fats is more important. One key feature of the western diet is a chronic metabolic surplus that is low in antioxidants but high in saturated fats, leading to storage of these surplus fats and eventually obesity. It is not disputed that obesity and asthma are linked; however, this relationship has not been well defined. Obesity can be differentiated by its low-grade chronic inflammatory state and already altered immune system because of an increase in proinflammatory adipokine and leptin/adiponectin levels. 56 This proinflammatory state found in obesity might be a critical player in the role of lipid mediators in asthmatic patients. A very telling study conducted by de Vries and Howie 57 showed that mice fed a diet high in saturated fat and allergen challenged before having an obese phenotype (between 6-8 weeks) displayed decreased proinflammatory cytokine production by lung draining lymph node cells and decreased eotaxin and lung eosinophilia compared with control mice on an 11% fat diet. Compared with a low-fat diet, asthmatic patients randomized to a high-fat diet showed acute increased airway neutrophilia and Toll-like receptor 4 mRNA expression and reductions in FEV 1 and forced vital capacity. These studies strongly suggest that a higher fat intake can lead to airway inflammatory and functional changes, which could worsen asthma symptoms.
CONJUGATED LINOLEIC ACID: THE BENEFICIAL n-6 FATTY ACID
Conjugated linoleic acid (cLA) has been touted for its favorable health implications, including its anticancer and anti-inflammatory properties and its association with reduced risk of cardiovascular events. [58] [59] [60] This n-6 fatty acid is synthesized in vivo by rumen bacteria from LA and might also be created during the heat processing of animal-derived foods, including milk and meat. Meat contributes approximately 25% to 30% of cLA in a Western diet, with the remainder from dairy. Although found in meat and dairy products, nonruminants and human subjects produce cLA from the trans-isomer of OA (vaccenic acid). This cLA formation is mediated by the entero-salivary microbiome through bacterial Δ 9 -desaturase activity. 60 Over the years, normal dietary consumption of cLA has decreased in the western diet because of changes in our consumption, some of which reflect a hearthealthy diet.
cLA was first recognized for its metabolic effects on obesity, body composition, and insulin insensitivity. 26 The predominant isomer of cLA in milk and meat is cis-9, trans-11-LA. This is in contrast to the commercial preparation, which is typically derived from sunflower oil, in which proportions of the 2 main isomers (cis-9, trans-11 and trans-10, cis-12) are equal. 26 Although specific effects have been attributed to individual isomers, many animal and human studies have used a combination of the 2 main isomers. In a study by MacRedmond et al, 61 investigators asked whether cLA would be efficacious as a dietary supplement for overweight patients with mild asthma. In this randomized, double-blind, placebo-controlled study subjects were given 4.5 g/d cLA or placebo for 12 weeks. The average body mass index of the group was 27.9 kg/m 2 . Measurements at week 12 compared with initial testing showed that the group receiving cLA had significant improvements in AHR, as measured based on the results of methacholine challenge (PC 20 ), and a significant decrease in body mass index with an associated reduction in the leptin/adiponectin ratio. Subjects also reported an increased tolerance for severe exercise. However, there were no differences in FEV 1 , systemic cytokine levels, or induced sputum cell counts. Much like n-3 PUFAs compete with n-6 PUFAs as substrates for enzymatic oxidation, cLA might compete with LA as a substrate for desaturases and elongases, resulting in an overall reduction in AA formation. cLA might also reduce eicosanoid formation through the transcriptional regulation of COX and LO and could mediate inflammation through PPARγ. 26 All of these mechanisms and effects on body composition would benefit asthmatic patients. 62 
CONCLUSIONS
Fatty acids play an essential role in the development and resolution of inflammatory pathways relevant to the pathophysiology of asthma. Although dietary interventions have been largely disappointing, there is ongoing interest to determine whether specific endogenous fatty acids can be used as therapeutic agents to resolve airway inflammation in asthmatic patients and, perhaps more importantly, to determine which type of asthmatic phenotype would gain the greatest benefit. Lipid mediators derived from omega-6 (Ω-6) and omega-3 (Ω-3) fatty acids. 
TABLE I
Observational studies on fatty acid exposure and asthma-related outcomes
Study design Study population Outcomes Results
Case-control study, United Kingdom 24 89 cases of asthma vs 89 community matched control subjects from local registries (mean age 43 y)
Fatty acid intake was determined by using FFQ, and erythrocyte membrane levels were determined by using mass spectrometry and odds of asthma.
n-3 fatty acids are not protective against asthma, and n-6 fatty acids are associated with lower risk of asthma.
Cross-sectional study, The Netherlands 25 13,820 subjects (age 20-59 y) Fatty acid intake was determined by using FFQ. Lung function was determined by using spirometry (FEV 1 and FVC) . A respiratory symptom questionnaire was used regarding reported wheeze, asthma, and COPD symptoms.
n-3 intake is not protective against COPD or asthma. High n-6 intake is associated with FEV 1 decrease, notably in smokers.
Case-control study, Germany 26 38 asthmatic patients with grass pollen allergy vs 19 age-matched healthy control subjects (age 18-45 y)
Lung function was measured by using spirometry, and bronchial hyperresponsiveness was measured using methacholine testing, allergen inhalation challenge, and measurement of exhaled NO. Stratification was according to low (Q25) and high (Q75) ratios of n-3 to n-6.
PUFA ratios (n-3/n-6) were less in asthmatic patients, and higher exhaled NO levels were present in Q25 asthmatic patients (or lower n-3/n-6 ratio group) compared with Q75 patients after bronchial inflammation.
There was a trend toward higher bronchial hyperreactivity in Q25, as indicated by greater change in FEV 1 .
Cross-sectional study, Germany 27 593 adults (age 20-64 y) sampled from a respiratory health survey
Fatty acid intake and metabolism were measured by using 3-d dietary survey and serum phospholipid extraction and evaluation. Lung function was measured by using FEV 1 and FVC, and bronchial hyperresponsiveness was measured by using methacholine challenge.
n-3 (DHA) was associated with improved lung function in men but not women. n-6 (dihomo-γ-linolenic acid) and monosaturated fatty acid (palmitoleic acid) were negatively associated with lung function in men but not women.
Cross-sectional study, Greece 28 1964 preschool children (age 24-72 mo) from nurseries and day care centers Three-day dietary was intake measured by using a home parental dietary intake record, and asthma outcomes were measured by using the ISAAC questionnaire.
Monosaturated fatty acid intake was associated with increased risk of asthma symptoms. Magnesium intake was associated with increased wheeze, whereas vitamin C and calcium appeared to be protective.
Cross-sectional study, Japan 29 452 children (age 3-6 y), including asthmatic and nonasthmatic patients Three-day dietary intake was measured by using a home-based parental dietary intake record. Asthma case status was ascertained by means of questionnaire.
There was no association between asthma diagnosis and any type of fatty acid intake, but there was a significant association with low intake of vitamins C and E.
Cross-sectional study, Finland 30 2679 children from 3 university hospitals from the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) nutrition study
Dietary intake was measured during the 8th month of pregnancy by using FFQ. Asthma risk was assessed at 5 y, as determined by using the ISAAC questionnaire.
Low intake of α-linolenic acid and total PUFAs during pregnancy was associated with increased risk of asthma in offspring, whereas low intake of AA and high intake of saturated fatty acids (palmitic acid) was associated with decreased risk of asthma in offspring at 5 y.
Cross-sectional study, Portugal 31 174 asthmatic patients (adults age >16 y), outpatient clinics Dietary intake over previous 12 mo was measured by using FFQ and asthma control based on a combination of lung function (FEV 1 ), exhaled NO levels, High n-6/n-3 ratio predicted higher exhaled NO levels, whereas high n-3, α-linolenic acid, and saturated fatty acid levels were associated with Wendell et al. Page 14
Asthma Control Questionnaire (ACQ) scores, and asthma quality of life (ALQ) test results.
lower exhaled NO levels.
Higher intake of n-3 was associated with better controlled asthma. There was no association between antioxidant vitamins and minerals and controlled asthma.
Cross-sectional study, Germany 32 2000 children (age 10 y) from 2 prospective birth cohort studies Fatty acid intake was measured by using FFQ, and atopic disease was measured by using specific serum IgE concentrations with stratification by FADS1 FADS2 genotype.
There was no associations between those with atopic disease or allergic sensitization and FADS genotype or fatty acid intake. Higher margarine intake was associated with risk of asthma in homozygotes for the major allele.
Cross-sectional study, Spain 33 638 Spanish schoolchildren (age 8-13 y)
Prevalence of current asthma was measured by using a parental questionnaire. Intake of lipids, fatty acids, and lipid-rich foods in a 3-d period was measured by using parental dietary record.
Energy from lipids, saturated fatty acids, and myristic and palmitic acids was significantly associated with current asthma, as well as butter intake. There was no association between asthma and intake of any other fatty acids, n-6/n-3 ratio, or consumption of margarine, milk products, fish, meat, eggs, or vegetable oils.
Cross-sectional study, Japan 34 25,033 children (age 6-15 y) using data from the Ryukyus Child Health Study (RYUCHS)
Symptoms of asthma were defined based on diagnostic criteria from ISAAC, and dietary intake was measured by using food questionnaires for children over a 1-mo period.
Intake of n-3 and n-6 fatty acids and linolenic acid was significantly associated with increased prevalence of wheeze. There was no association between consumption of α-LA, EPA, DHA, AA, or n-3/n-6 ratio with the prevalence of wheeze. Total fat, saturated fatty acids, and monounsaturated fatty acids were not related to wheeze.
Cross-sectional study, Australia 35 1,601 adults with and without known asthma (age 20-44 y)
Dietary intake was measured by using FFQ. Asthma and atopy were measured based on respiratory questionnaire results, skin prick test results, lung function (FEV 1 ), and methacholine challenge results for bronchial hyperresponsiveness and plasma fatty acid levels.
There was no association between any plasma fatty acid levels and atopy or asthma, except dihomo cLA, an n-6 fatty acid, which was positively associated with asthma diagnosis.
Nested case-control study, Germany 36 526 children (age 8-11 y) from Munich from ISAAC phase II Plasma fatty acid levels were measured. Asthma Symptoms or diagnosis were determined based on respiratory questionnaires completed by parents. Atopy was measured by using skin prick tests, and bronchial hyperresponsiveness was measured after hypertonic saline challenge.
EPA levels were not associated with asthma or lung function, whereas linolenic levels were associated (both with n-3 fatty acids). There was a strong association between AA and asthma (n-6 fatty acid) with FEV 1 decreases. LA was negatively associated with current asthma and an incremental change in FEV 1 . The n-6/n-3 ratio, palmitic acid, and OA had no association with asthma or lung function.
Longitudinal analysis 37 20-y follow-up in a cohort of 4,162 Americans (age 18-30 y) without a history of asthma Diet was assessed by using FFQ at 3 time points in a 20-y period. Incidents of self-reported asthma were determined based on a physician's diagnosis and/or use of asthma medications.
Four hundred forty-six cases of incident asthma were identified in a 20-y follow-up, and n-3 fatty acid intake was inversely associated with incident asthma.
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Study design Study population Outcomes Results
Cross-sectional study, United States and Canada 38 2,112 twelfth-grade students Lung function was determined by using a respiratory questionnaire. Dietary intake of antioxidants, micronutrients, retinol, and fatty acids were measured.
Low dietary fruit intake and n-3 fatty acid intake were associated with increased odds of respiratory symptoms (chronic bronchitis, wheeze, and asthma). Lower vitamin C intake was seen in smokers, and they had higher ORs for respiratory symptoms.
Cross-sectional study, Finland 39 2441 children (age 5 y) participating in a diabetes mellitus type 1 study cohort
Dietary intake of fats in the 8th month of pregnancy was determined by using FFQ. A parental record of allergic disease was determined by using the ISACC questionnaire in offspring at 5 y. Exhaled NO levels were lower in the n-3 PUFA group before and after allergen challenge compared with the placebo group. Serum eosinophil counts, eosinophilic cationic protein levels, and in vitro CysLT release are decreased in the n-3 PUFA group.
Randomized controlled trial, Australia 46 616 pregnant women whose unborn children were at high risk of asthma based on family history HDM avoidance intervention; dietary supplementation with daily n-3-rich tuna fish oil (500 mg), margarines, and cooking oils or placebo (Sunola oil) starting at 6 mo Asthma symptoms or diagnosis or treatment were assessed by using a parental questionnaire, atopic status was determined by using skin prick testing, and serum IgE levels in offspring were measured at 18 mo.
There was a lower prevalence of wheeze in the diet intervention group, but physiciandiagnosed asthma was not reduced. HDM reduction reduced use of oral steroids but did not affect outcomes.
Randomized, double-blind, placebo-controlled trial, Denver, Colorado 47 43 children (age 6-14 y) with mild-tomoderate persistent asthma
Enriched n-3 fatty acid and antioxidant (3 g of EPA, 1.6 g of DHA, 3.0 g of GLA; vitamins E and C, β-carotene, taurine, zinc, copper, selenium, molybdenum, and calcium) formula vs control (same caloric amount blended with 100% high-oleic safflower oil) formula for 12-wk trial as between meal snack or at mealtime
Numbers of asthma-free days were determined, and assessment of fatty acid levels and safety outcomes was performed. Measurement of asthmatic symptoms, skin prick test responses, serum eosinophilic cationic protein levels, eosinophil counts, serum IgE levels, exhaled NO levels, and methacholine challenge test results were determined.
There were no differences in asthmafree days between the 2 groups. Higher exhaled NO levels were seen in the control group compared with the treatment group at 4, 8, and 12 wk. Higher EPA levels were found in serum and PBMC phospholipids in the treatment group. No differences were found in adverse events.
